Skip Nav Destination
Issues
1 June 2022
-
Cover Image
Cover Image
Fluorescence lifetime microscopy image of a nasal cavity tumor resected from a patient with oral squamous cell carcinoma, systemically injected with panitumumab-IRDye 800CW. High EGFR-expressing tumor cell clusters (red) are clearly delineated from nonspecific dye uptake in normal oral tissue (green). For details, see the article by Pal and colleagues on page 2373 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Review
CCR Drug Updates
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1–High NSCLC
Oladimeji Akinboro; Erin Larkins; Lee H. Pai-Scherf; Luckson N. Mathieu; Yi Ren; Joyce Cheng; Mallorie H. Fiero; Wentao Fu; Youwei Bi; Shyam Kalavar; Samina Jafri; Pallavi S. Mishra-Kalyani; Jeanne Fourie Zirkelbach; Hongshan Li; Hong Zhao; Kun He; Whitney S. Helms; Meredith K. Chuk; Min Wang; Ilynn Bulatao; Jonathan Herz; Blaire L. Osborn; Yuan Xu; Jiang Liu; Yutao Gong; Sharon Sickafuse; Rebecca Cohen; Martha Donoghue; Richard Pazdur; Julia A. Beaver; Harpreet Singh
Research Briefs: Clinical Trial Brief Reports
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy
Sunyoung Lee; Rachna T. Shroff; Shalini Makawita; Lianchun Xiao; Anaemy Danner De Armas; Priya Bhosale; Kavitha Reddy; Ahmed Shalaby; Kanwal Raghav; Shubham Pant; Robert A. Wolff; Milind Javle
Clinical Trials: Targeted Therapy
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Christopher J. Sweeney; Ivor J. Percent; Sunil Babu; Jennifer L. Cultrera; Bryan A. Mehlhaff; Oscar B. Goodman; David S. Morris; Ian D. Schnadig; Costantine Albany; Neal D. Shore; Paul R. Sieber; Susan C. Guba; Wei Zhang; Volker Wacheck; Gregory P. Donoho; Anna M. Szpurka; Sophie Callies; Boris Kin Lin; Johanna C. Bendell
Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer
Joline S.J. Lim; Andrea L.A. Wong; Samuel G.W. Ow; Natalie Y.L. Ngoi; Gloria H.J. Chan; Yvonne L.E. Ang; Wan Qin Chong; Siew Eng Lim; Yi Wan Lim; Matilda Lee; Joan R.E. Choo; Hon Lyn Tan; Wei Peng Yong; Ross A. Soo; David S.P. Tan; Cheng Ean Chee; Raghav Sundar; Kritika Yadav; Supriya Jain; Lingzhi Wang; Bee Choo Tai; Boon Cher Goh; Soo-Chin Lee
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Atish D. Choudhury; Celestia S. Higano; Johann S. de Bono; Natalie Cook; Dana E. Rathkopf; Kari B. Wisinski; Juan Martin-Liberal; Mark Linch; Elisabeth I. Heath; Richard D. Baird; Javier García-Carbacho; Miguel Quintela-Fandino; Simon T. Barry; Elza C. de Bruin; Steve Colebrook; George Hawkins; Teresa Klinowska; Brijesh Maroj; Ganesh Moorthy; Peter G. Mortimer; Michele Moschetta; Myria Nikolaou; Liz Sainsbury; Geoffrey I. Shapiro; Lillian L. Siu; Aaron R. Hansen
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Andrew B. Lassman; Juan Manuel Sepúlveda-Sánchez; Timothy F. Cloughesy; Miguel J. Gil-Gil; Vinay K. Puduvalli; Jeffrey J. Raizer; Filip Y.F. De Vos; Patrick Y. Wen; Nicholas A. Butowski; Paul M.J. Clement; Morris D. Groves; Cristóbal Belda-Iniesta; Pierre Giglio; Harris S. Soifer; Steven Rowsey; Cindy Xu; Francesca Avogadri; Ge Wei; Susan Moran; Patrick Roth
Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
Qinglei Gao; Jianqing Zhu; Weidong Zhao; Yi Huang; Ruifang An; Hong Zheng; Pengpeng Qu; Li Wang; Qi Zhou; Danbo Wang; Ge Lou; Jing Wang; Ke Wang; John Low; Beihua Kong; Abdul Malik Rozita; Lim Chun Sen; Rutie Yin; Xing Xie; Jihong Liu; Wei Sun; Jingya Su; Chunyi Zhang; Rongyu Zang; Ding Ma
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
Margarita Majem; Jonathan W. Goldman; Thomas John; Christian Grohe; Konstantin Laktionov; Sang-We Kim; Terufumi Kato; Huu Vinh Vu; Shun Lu; Shanqing Li; Kye Young Lee; Charuwan Akewanlop; Chong-Jen Yu; Filippo de Marinis; Laura Bonanno; Manuel Domine; Frances A. Shepherd; Shinji Atagi; Lingmin Zeng; Dakshayini Kulkarni; Nenad Medic; Masahiro Tsuboi; Roy S. Herbst; Yi-Long Wu
Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
Josep M. Llovet; Amit G. Singal; Augusto Villanueva; Richard S. Finn; Masatoshi Kudo; Peter R. Galle; Masafumi Ikeda; Sophie Callies; Louise M. McGrath; Chunxiao Wang; Paolo Abada; Ryan C. Widau; Elena Gonzalez-Gugel; Andrew X. Zhu
Clinical Trials: Immunotherapy
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
Michael J. Wagner; Yuzheng Zhang; Lee D. Cranmer; Elizabeth T. Loggers; Graeme Black; Sabrina McDonnell; Shannon Maxwell; Rylee Johnson; Roxanne Moore; Pedro Hermida de Viveiros; Lauri Aicher; Kimberly S. Smythe; Qianchuan He; Robin L. Jones; Seth M. Pollack
Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer
Alberto A. Chiappori; Ben Creelan; Tawee Tanvetyanon; Jhanelle E. Gray; Eric B. Haura; Ram Thapa; Margaret L. Barlow; Zhihua Chen; Dung Tsa Chen; Amer A. Beg; Theresa A. Boyle; Julio Castro; Liza Morgan; Erick Morris; Mehreteab Aregay; Felipe K. Hurtado; Luigi Manenti; Scott Antonia
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Christine H. Chung; Jiannong Li; Conor E. Steuer; Priyanka Bhateja; Matthew Johnson; Jude Masannat; Maria I. Poole; Feifei Song; Juan C. Hernandez-Prera; Helen Molina; Bruce M. Wenig; Sunil Kumar; Charlotte Kuperwasser; Philip J. Stephens; Joaquim M. Farinhas; Dong M. Shin; Julie A. Kish; Jameel Muzaffar; Kedar Kirtane; James W. Rocco; Michael J. Schell; Nabil F. Saba; Marcelo Bonomi
Precision Medicine and Imaging
Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer
Adrienne G. Waks; Dewey Kim; Esha Jain; Craig Snow; Gregory J. Kirkner; Shoshana M. Rosenberg; Coyin Oh; Philip D. Poorvu; Kathryn J. Ruddy; Rulla M. Tamimi; Jeffrey Peppercorn; Lidia Schapira; Virginia F. Borges; Steven E. Come; Elena F. Brachtel; Ellen Warner; Laura C. Collins; Ann H. Partridge; Nikhil Wagle
Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
Brittany L. Bychkovsky; Tianyu Li; Jilliane Sotelo; Nabihah Tayob; Joanna Mercado; Israel Gomy; Anu Chittenden; Sarah Kane; Samantha Stokes; Melissa E. Hughes; Ji Seok Kim; Renato Umeton; Mark M. Awad; Panagiotis A. Konstantinopoulos; Matthew B. Yurgelun; Brian M. Wolpin; Mary-Ellen Taplin; Randall E. Newmark; Bruce E. Johnson; Neal I. Lindeman; Laura E. MacConaill; Judy E. Garber; Nancy U. Lin
Artificial Intelligence-Assisted Serial Analysis of Clinical Cancer Genomics Data Identifies Changing Treatment Recommendations and Therapeutic Targets
Catherine G. Fischer; Aparna Pallavajjala; LiQun Jiang; Valsamo Anagnostou; Jessica Tao; Emily Adams; James R. Eshleman; Christopher D. Gocke; Ming-Tseh Lin; Elizabeth A. Platz; Rena R. Xian
First Clinical Results of Fluorescence Lifetime-enhanced Tumor Imaging Using Receptor-targeted Fluorescent Probes
Rahul Pal; Marisa E. Hom; Nynke S. van den Berg; Thinzar M. Lwin; Yu-Jin Lee; Andrey Prilutskiy; William Faquin; Eric Yang; Srinivas V. Saladi; Mark A. Varvares; Eben L. Rosenthal; Anand T.N. Kumar
VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Vinton W.T. Cheng; Nicholas de Pennington; Rasheed Zakaria; James R. Larkin; Sébastien Serres; Manjima Sarkar; Matthew A. Kirkman; Claire Bristow; Paula Croal; Puneet Plaha; Leticia Campo; Michael A. Chappell; Simon Lord; Michael D. Jenkinson; Mark R. Middleton; Nicola R. Sibson
Translational Cancer Mechanisms and Therapy
Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression
Matthew L. Hemming; Patrick Bhola; Michael A. Loycano; Justin A. Anderson; Madeleine L. Taddei; Leona A. Doyle; Elizaveta Lavrova; Jessica L. Andersen; Kelly S. Klega; Morgan R. Benson; Brian D. Crompton; Chandrajit P. Raut; Suzanne George; Anthony Letai; George D. Demetri; Ewa Sicinska
Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth
Krishna Madhavan; Ilango Balakrishnan; Senthilnath Lakshmanachetty; Angela Pierce; Bridget Sanford; Susan Fosmire; Hanan B. Elajaili; Faye Walker; Dong Wang; Eva S. Nozik; Siddhartha S. Mitra; Nathan A. Dahl; Rajeev Vibhakar; Sujatha Venkataraman
HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma
Jo Sasame; Naoki Ikegaya; Masahito Kawazu; Manabu Natsumeda; Takahiro Hayashi; Masataka Isoda; Kaishi Satomi; Arata Tomiyama; Akito Oshima; Hirokuni Honma; Yohei Miyake; Katsuhiro Takabayashi; Taishi Nakamura; Toshihide Ueno; Yuko Matsushita; Hiromichi Iwashita; Yu Kanemaru; Hidetoshi Murata; Akihide Ryo; Keita Terashima; Shoji Yamanaka; Yukihiko Fujii; Hiroyuki Mano; Takashi Komori; Koichi Ichimura; Daniel P. Cahill; Hiroaki Wakimoto; Tetsuya Yamamoto; Kensuke Tateishi
Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial
Kaspar Draaisma; C. Mircea S. Tesileanu; Iris de Heer; Martin Klein; Marion Smits; Jaap C. Reijneveld; Paul M. Clement; Filip Y.F. de Vos; Antje Wick; Paul J. Mulholland; Martin J.B. Taphoorn; Michael Weller; Olivier L. Chinot; Johan M. Kros; Tina Verschuere; Corneel Coens; Vassilis Golfinopoulos; Thierry Gorlia; Ahmed Idbaih; Pierre A. Robe; Martin J. van den Bent; Pim J. French
Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma
Roger Esteban-Fabró; Catherine E. Willoughby; Marta Piqué-Gili; Carla Montironi; Jordi Abril-Fornaguera; Judit Peix; Laura Torrens; Agavni Mesropian; Ugne Balaseviciute; Francesc Miró-Mur; Vincenzo Mazzaferro; Roser Pinyol; Josep M. Llovet
Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC
Pedro Rocha; Jiexin Zhang; Raquel Laza-Briviesca; Alberto Cruz-Bermúdez; Neus Bota-Rabassedas; Beatriz Sanchez-Espiridon; Katsuhiro Yoshimura; Carmen Behrens; Wei Lu; Ximing Tang; Apar Pataer; Edwin R. Parra; Cara Haymaker; Junya Fujimoto; Stephen G. Swisher; John V. Heymach; Don L. Gibbons; J. Jack Lee; Boris Sepesi; Tina Cascone; Luisa M. Solis; Mariano Provencio; Ignacio I. Wistuba; Humam Kadara
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds